AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03183947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERQ
Description: To assess emotion regulation strategies before and after neurofeedback training (patients: day 3\&4; controls: day 2\&3) and after 4 weeks during a telephone interview
Study NCT03420625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calf NMES
Description: Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
Study NCT00763529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone furoate cream 0.1% applied once daily
Study NCT00763529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Fluticasone propionate cream 0.05% applied twice daily
Study NCT06352983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dental prosthesis
Description: Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thioguanine
Description: see detailed protocol description
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: see detailed protocol description
Study NCT06352983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed dental prosthesis
Description: Fixed dentals prosthesis made out of high translucent zirconium dioxide with or without a porcelain veneer.
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: see detailed protocol description
Study NCT01598545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
Study NCT03683329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic de-escalation
Description: All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
Study NCT03683329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
Study NCT04130217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of positive end expiratory pressure in ventilated patients
Description: patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
Study NCT04130217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: addition of positive end expiratory pressure and recruitment maneuver in ventilated patients
Description: patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
Study NCT01086345 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgery
Description: Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
Study NCT00967629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevelamer Carbonate
Description: This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
Study NCT00967629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Calcium Carbonate
Description: This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
Study NCT01086345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01086345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00350987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: a strategy based on PCT guided AB therapy
Description: In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
Study NCT00350987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a strategy based on PCT guided AB therapy
Description: In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
Study NCT03460145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Oil on Nasal Strip (Lx)
Description: Usage of Aromatherapy for Preoperative Anxiety
Study NCT03460145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strip without Lavender Oil (Px)
Description: Strip without Lavender Oil (Px)
Study NCT03460145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1% (10mg/mL)
Study NCT03460145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 1 % Injectable Suspension
Description: Propofol 1% (10mg/mL)
Study NCT03639220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
Study NCT03639220 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Therapy (PBMT)
Description: Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
Study NCT00375791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: 100 - 150 mg daily
Study NCT00375791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg twice weekly
Study NCT03666325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
Study NCT03666325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
Study NCT01122589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/CBT
Description: 6 sessions of in jail MI/CBT counseling will be administered.
Study NCT01561378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart insulin
Description: 40 IU of aspart insulin (200 microliters per nostril) will be administered intranasally using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Study NCT01117441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: see detailed protocol description
Study NCT01122589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)
Description: a series of six weekly 30-45 minutes general wellness videos
Study NCT05066568 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active Tracranial Direct Current Stimulation
Description: Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Stimulation time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.
Study NCT01561378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Study NCT01561378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal mucosal atomizer device
Description: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Study NCT05066568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hypnotic analgesia suggestion
Description: The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
Study NCT05066568 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rest
Description: The patient is asked to remain seated still for 20 minutes.
Study NCT05066568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active tDCS + Hypnotic analgesia suggestion
Description: Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 2mA Intervention time: 20 min The current ramps up during 30 seconds reaching 2mA, staying this way until the last 30 seconds of stimulation, in wich the current slowly decreases to zero.~The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
Study NCT05066568 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham tDCS + Hypnotic analgesia suggestion
Description: Site: dorsolateral prefrontal cortex. F3 anode and F4 catode. Electrode area: 35cm2 Current Intensity: 0mA Intervention time: 20 min The current is turned off after 30 seconds. The hypnotic induction protocol was standardized to be applied equally to all subjects. The protocol for hypnotic analgesia begins with an induction with a sequence of suggestions for the subjects to focus their attention on an individual stimulus, associated with progressive relaxation. After that, direct suggestions are given for comfort and pain reduction. The intervention lasts 20 minutes, with 12 minutes of induction and 8 minutes of hypnotic suggestions to reduce pain and leave the trance.
Study NCT02238132 — intervention group
Intervention type: DRUG
Intervention: ATROVENT® inhalets
Study NCT03785691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Study NCT03785691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Study NCT03785691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Study NCT02476188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sample of Blood
Study NCT02476188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sample of Blood
Study NCT03255434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
Study NCT03255434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin LBM
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
Study NCT03840382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-PrEP Intervention
Description: Telemedicine conferences with PrEP-specialists
Study NCT03332251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posture Correction Girdle
Description: Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
Study NCT00932724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY-503
Description: Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Study NCT00932724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Study NCT00934180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 1 x 8 mg Orally Disintegrating Tablet
Study NCT00934180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran®
Description: 1 x 8 mg ODT
Study NCT01561378 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal mucosal atomizer device
Description: Insulin and placebo will be drawn into identical syringes. Nurses will administer the insulin or placebo by connecting the mucosal atomizer device (MAD) to the syringe, placing the MAD tip in the nostril and compressing the syringe plunger to spray atomized solution into the nasal cavity.
Study NCT01212107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF Receptor
Description: LY2874455 administered orally.
Study NCT00835172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg Tablets
Description: 1 x 4 mg, single-dose non-fasting
Study NCT00835172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARYL® 4 mg Tablets
Description: 1 x 4 mg, single-dose non-fasting
Study NCT04501718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With Temozolomide and Etoposide Capsules
Description: Apatinib mesylate tablets: Oral, 250mg, qd. Take the medicine with warm water half an hour after a meal (the daily medicine should be taken at the same time as possible).~28 days is a cycle, and the medication is administered until the disease progresses (PD), intolerable toxicity occurs or the patient withdraws informed consent. The longest period does not exceed 12 cycles. The treatment after 12 cycles is determined by the investigator.
Study NCT00834197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg (Orally Disintegrating) Tablets
Description: 1 x 15 mg, single-dose non-fasting
Study NCT00834197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON SolTab® 15 mg Orally Disintegrating Tablets
Description: 1 x 15 mg, single-dose non-fasting
Study NCT05919563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Observational study; annual MRI for first 5 years only to monitor changes in the injection site
Study NCT01905397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure wound therapy
Description: The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
Study NCT02549911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPEC,Chemotherapy AND surgery
Description: 1. HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~2. chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~3. surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~4. after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles
Study NCT02718794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulation training
Description: spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
Study NCT02718794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Problem-based learning
Description: spend 3 hours for PBL steps with each of 10 nurse anesthetist students
Study NCT03206034 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stylistic Memory Enhancement
Study NCT03206034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stylistic Memory Enhancement
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ferrous fumarate
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ferrous fumarate
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for ferinject
Study NCT01975272 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ferinject
Study NCT03209024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Handwritten logbook recording of home blood pressure readings
Description: Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
Study NCT03209024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone assisted wireless recording of home blood pressure readings
Description: Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
Study NCT01166815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulphate
Description: Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
Study NCT01166815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
Study NCT01812629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Infant formula to be fed ad libitum